A blood test using CRISPR to detect the BRAF V600E mutation in metastatic melanoma
Tests a blood-based method to find BRAF V600E in people with metastatic melanoma.
Plain-language title generated from the registry record
Registry title: Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
Key facts
- Where
- Brno, CzechiaSee the site
Where in Czechia
- Masaryk Memorial Cancer InstituteBrno, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Masaryk Memorial Cancer Institute
- Trial code
- NCT07870265
- Record updated
- 16 October 2026
- Original description
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.Read full original descriptionShow less
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.
Inclusion: Age ≥ 18 years; Subject willing and able to provide written informed consent for biological sample collection; Ability to communicate effectively with the investigator in the local language, as well as the ability to understand and comply with study requirements; Histologically confirmed malignant melanoma; Radiologically or histologically confirmed disease relapse; Feasibility/possibility of peripheral blood sampling for ctDNA analysis; Documented, known *BRAF* mutation status (wild-type vs. V600E).
Exclusion: Patients receiving palliative care with an estimated life expectancy ≤ 3 months; Severe alcohol and/or drug abuse during therapy; Operable disease relapse; Age under 18 years; Pregnant or breastfeeding women; Inability to obtain a valid biological sample for molecular analysis.